Abstract
Biocryst Pharmaceuticals will report third-quarter 2026 financial results on November 4, 2026, Pre-Mkt; this preview compiles consensus forecasts, last quarter’s scorecard, and the key watch items within its commercial franchise and near-term catalysts.
Market Forecast
Consensus modeling points to revenue of 165.67 million US dollars for the current quarter, implying 1.66% year-over-year growth, with EBIT around 38.91 million (up 29.76% year over year) and adjusted EPS of 0.08 (up 138.50% year over year). No explicit gross margin or net margin guidance has been communicated for the quarter.
The main business is expected to remain supported by steady demand for the company’s core therapy, with recent regulatory and formulation milestones broadening its addressable population and supporting revenue quality and visibility into year-end.
The most promising segment is the HAE franchise led by the core therapy, which generated 148.30 million US dollars in the first quarter of 2026, up 11.00% year over year, with management and external models anticipating continued momentum as new geographies, younger age groups, and a more convenient formulation contribute to adherence and persistence.
Last Quarter Review
In the quarter ended June 30, 2026, Biocryst Pharmaceuticals delivered revenue of 218.25 million US dollars, a gross profit margin of 74.43%, GAAP net profit attributable to the parent of 78.40 million US dollars, a net profit margin of 35.92%, and adjusted EPS of 0.30 (up 650.00% year over year).
A key financial highlight was a clean top- and bottom-line beat relative to market expectations and a subsequent increase in the company’s 2026 revenue outlook to 690.00–715.00 million US dollars, reflecting confidence in commercial execution and operating discipline.
Main business dynamics were healthy: Products revenue reached 157.51 million US dollars, while total revenue advanced 33.61% year over year, with licensing and other revenue contributing 60.74 million US dollars and supporting earnings leverage.
Current Quarter Outlook
Core commercial engine this quarter
The quarter hinges on steady, execution-driven growth across the HAE prophylaxis franchise, where persistency, adherence, and payer stability influence gross-to-net dynamics and realized revenue. The recent supplemental approval in the United States for a pellet formulation enables once-daily oral administration that can be poured directly into the mouth, improving usability for patients who struggle with capsules and potentially supporting adherence and therapy continuity. Complementing this, Japan’s approval for younger children (ages 2 to under 12) expands the treated population and sets up incremental international contributions as reimbursement and launch timing progress.
While consensus implies only modest top-line expansion this quarter versus the strong prior quarter, channel inventories, script trends, and any commentary on patient adds remain pivotal to the reported revenue cadence. With the company’s reported gross margin at 74.43% last quarter, investors will assess whether revenue mix (Products versus Licenses and other) tracks in a similar direction, as mix will influence quarterly margin volatility. Given the step-up in revenue from licensing in recent periods, one watch item is the timing of any milestone or collaboration-related revenue this quarter, which can amplify EBIT and EPS variance relative to sales growth.
Largest growth opportunity
The most material growth runway remains the HAE franchise, where pediatric expansion, formulation convenience, and geographic rollouts create multiple vectors for incremental demand. The pediatric approval in Japan opens access for an age group historically underserved by oral prophylaxis options, and the granule formulation that can be taken with water, milk, or soft food should enhance caregiver convenience and patient adherence. The US pellet formulation approval adds another convenience layer for older patients and adolescents, potentially improving prescription conversion and persistency where pill burden or swallowing challenges present barriers.
Although not revenue-accretive in the near term, pipeline optionality shapes the forward narrative and can influence the multiple investors assign to current cash flows. A long-acting injectable candidate in a late-stage study is designed to complement the oral therapy, potentially allowing the company to compete across patient preferences; enrollment milestones and development updates can be sentiment drivers this quarter even if no registrational data is expected yet. Together, these developments underpin the buy-side view that the franchise can sustain growth beyond near-term competitive noise, provided real-world outcomes, safety signals, and payer coverage remain supportive.
Stock price swing factors this quarter
Short-term share performance will likely be most sensitive to the magnitude of top-line variance versus the 165.67 million US dollars consensus, the trajectory of operating leverage, and any updates to full-year revenue commentary. With adjusted EPS modeled at 0.08 this quarter, mix effects between product sales and licensing can produce outsized swings in EBIT and EPS; investors will parse whether high-margin contribution is repeatable or one-off. Beyond the P&L, the company’s cost realignment initiatives and disclosed severance-related items indicate an ongoing effort to streamline R&D infrastructure; commentary on the timing, magnitude, and cash impacts can influence how the market extrapolates 2027+ operating margin potential.
Competitive developments remain an overhang-to-upside toggle: stronger data from an oral competitor has raised questions around long-term share retention for the core therapy, but near-term consensus still embeds sequential growth. Management’s color on patient additions, discontinuations, switch dynamics, and payer feedback will be closely read to assess resilience against those competitive pressures. Finally, execution in international markets—especially the cadence of pediatric launches and reimbursement approvals—could provide upside to consensus if timelines accelerate or early uptake surpasses expectations.
Analyst Opinions
Across identifiable updates in the past six months, the weight of opinion skews bullish, with roughly three bullish views versus one bearish, implying approximately 75% of tracked notes tilt positive. The bullish camp points to persistent commercial momentum in the core therapy, expanding pediatric access and more convenient formulations, and tangible operating discipline as the company streamlines its R&D footprint to prioritize external innovation and capital efficiency.
Cantor Fitzgerald, through analyst Steven Seedhouse, maintained a Buy rating with a 29.00 US dollars price target, citing confidence in continued expansion of the HAE franchise and reinforcing the view that revenue growth can be sustained while operating leverage improves. This perspective aligns with the most recent quarterly performance, where revenue and EPS exceeded consensus, and with the regulatory wins—Japan’s pediatric approval and the US supplemental approval for the pellet formulation—that address convenience and access barriers and can translate into better persistency. From a near-term standpoint, Cantor’s constructive stance implies that even a modest revenue beat combined with disciplined expense control could support an upside EPS surprise against the 0.08 consensus.
Two recent notes from Wedbush retained an Outperform rating while adjusting price targets within a range of 18.00–20.00 US dollars, reflecting a balanced but constructive stance on execution through year-end. Wedbush’s framework emphasizes the interplay between product mix and licensing contributions on quarter-to-quarter profitability, and the belief that operating initiatives are starting to enhance the earnings power of the model. With consensus looking for 38.91 million US dollars in EBIT and a 138.50% year-over-year increase in adjusted EPS to 0.08 this quarter, Wedbush’s Outperform stance effectively argues that upside is achievable if revenue tracks near or above 165.67 million US dollars and if mix and cost controls again support margin resilience.
The positive institutional tone is also evident in recent previews that coalesce around a slight revenue increase versus the prior year’s quarter and an outsized EPS inflection on improved operating efficiency. Strategists highlighting the new formulation approvals in the United States and pediatric expansion in Japan interpret these milestones as catalysts that can improve the quality and durability of revenue by lifting adherence and reducing friction in patient starts. While competitive commentary remains part of every cross-check, the majority view expects the core therapy’s growth to continue near term, given payer familiarity, established access, and the incremental convenience delivered by the pellet and granule options.
Aggregating the themes from the bullish side, the majority expectation for this print is as follows: revenue landing near 165.67 million US dollars with a path to a modest beat if channel data and international contributions hold; EBIT tracking above 38.91 million US dollars if licensing or milestones appear in the quarter; and adjusted EPS potentially exceeding 0.08 on mix and operating discipline. Analysts in this camp explicitly link their conviction to operational markers management can deliver or update on the call: the pace of pediatric launches, formulary and access stability, and evidence of sustained patient persistency. Many also point out that the updated 2026 revenue outlook range of 690.00–715.00 million US dollars provides a useful reference for how management views underlying demand into next year; reiterated confidence here would bolster the bull case that current-quarter puts and takes are consistent with a durable earnings trajectory.
In short, the majority of institutional voices remain positive heading into November 4, 2026, Pre-Mkt, looking for steady commercial execution and reinforcing catalysts to support an incremental beat-and-raise setup. The bar on revenue growth this quarter is not high at 1.66% year over year, but the combination of improving operating mix, visible geographic and age-segment expansion, and a more efficient R&D operating model is central to why most analysts expect the company to maintain or extend its earnings inflection through the back half of the year.Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments